Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
Breast Cancer. 2023 Jul;30(4):606.
doi: 10.1007/s12282-023-01468-z.
1 Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan. hidekoyamauchi@gmail.com.
2 St. Luke's International Hospital, Tokyo, Japan. hidekoyamauchi@gmail.com.
3 Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan.
4 Kyoto University Hospital, Kyoto, Japan.
5 National Cancer Center Hospital, Tokyo, Japan.
6 Showa University Hospital, Tokyo, Japan.
7 The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
8 AstraZeneca, Gaithersburg, MD, USA.
9 Frontier Science (Scotland) Ltd, Kingussie, UK.
10 Breast International Group (BIG), Brussels, Belgium.
11 NSABP Foundation/NRG Oncology, Pittsburgh, PA, USA.
12 University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA.
13 The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, and The Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London, London, UK.